04:28 AM EDT, 10/16/2024 (MT Newswires) -- Hutchmed ( HCM ) said Wednesday a phase 2 study of a combination therapy it co-developed with AstraZeneca ( AZN ) showed clinically meaningful and durable objective response rates in patients with a type of non-small cell lung cancer.

The study showed that the safety and tolerability of the combination of Tagrisso and Orpathys, co-developed by AstraZeneca ( AZN ) and Hutchmed ( HCM ), was consistent with the known safety profiles of the combination, with no new safety signals identified, Hutchmed ( HCM ) said.

Price: 18.81, Change: +0.01, Percent Change: +0.05